The product approval for Bactiguard’s endotracheal tubes has been announced by the Indian Ministry of Health & Family Welfare. This means that Bactiguard can offer its complete portfolio of products for effective and safe infection prevention in one of the largest and fastest growing markets in the world.
The Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health & Family Welfare, has announced the regulatory approval of Bactiguard’s endotracheal tubes for infection prevention (BIP ETT and BIP ETT Evac) in India.
”Blood stream infections, respiratory and urinary tract infections are the most frequent and serious healthcare associated infections, especially in intensive care settings. We are therefore very pleased that we can now offer products to address all of those in India. A few months ago, our central venous catheters were approved and since a couple of years our urinary catheters are available on the market. The new approval means that we can offer more complete protection for the most vulnerable patients, which will save many lives and reduce suffering for both patients and their relatives”, says Cecilia Edström, CFO.
Bactiguard’s urinary catheter (BIP Foley Catheter) was launched in India in early 2016 and in August this year, the Ministry of Health & Family Welfare approved Bactiguard’s central venous catheter (BIP CVC). Following the product approval for BIP ETT and BIP ETT Evac, Bactiguard can now offer its complete range of infection prevention products in the Indian market.
For further information, please contact:
Cecilia Edström, SVP Sales and New business, cell phone: +46 72 226 23 28
